Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.5
4.5
Journals
Biomimetics
Special Issues
Blood-Compatible Materials: Preparation, Modification and Functionalization
share announcement

Blood-Compatible Materials: Preparation, Modification and Functionalization

A special issue of Biomimetics (ISSN 2313-7673). This special issue belongs to the section "Biomimetics of Materials and Structures".

Deadline for manuscript submissions: closed (31 July 2023) | Viewed by 6608

Special Issue Editor

Dr. Xiaoli Liu

E-Mail Website
Guest Editor
Key Laboratory of Polymeric Material Design and Synthesis for Biomedical Function, College of Chemistry, Chemical Engineering and Materials Science, Soochow University, 199 Ren−Ai Road, Suzhou 215123, China
Interests: blood-compatible materials; heparin mimetic materials; protein–surface interactions; cell–surface interactions; surface modification and biofunctionalization of materials for microfluidic chips
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Blood-compatible materials are materials that can be used in contact with blood. They are widely required in a variety of medical devices. The range of applications includes vascular access products, extracorporeal blood treatments, and cardiovascular implantable medical devices. Despite more than 70 years of continuous efforts, materials that are ideally compatible with blood in all aspects have not been obtained. All of the medical devices that contact the blood stream are susceptible to thrombotic complications even in the presence of anticoagulants. With an ever-increasing use of blood-contacting devices, it is still an urgent need to develop truly blood-compatible materials.

This Special Issue on “Blood-Compatible Materials: Preparation, Modification and Functionalization” calls for contributions from researchers in all realms of blood-compatible materials. This theme is inherently interdisciplinary and thus welcomes theoretical, experimental, and review contributions from physicists, chemists, biologists, material scientists, engineers, and those who are engaged and interested in this fast-growing field.

Potential topics include, but are not limited to, the following:

  • Antifouling materials;
  • Bioactive materials;
  • Biomimetic materials;
  • Blood–material interactions;
  • Computer simulation for design of blood-compatible materials;
  • Characterization tools/protocols to evaluate blood compatibility.

Dr. Xiaoli Liu
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomimetics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • blood compatibility
  • thrombosis
  • surface modification
  • protein adsorption
  • antifouling
  • cell behavior 
  • biomimetic

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

12 pages, 2421 KiB  
Article
Unraveling the Mechanism of Platelet Aggregation Suppression by Thioterpenoids: Molecular Docking and In Vivo Antiaggregant Activity
by Liliya E. Nikitina, Pavel S. Bocharov, Alexander A. Ksenofontov, Elena V. Antina, Ilmir R. Gilfanov, Roman S. Pavelyev, Olga V. Ostolopovskaya, Inna V. Fedyunina, Zulfiya R. Azizova, Svetlana V. Pestova, Evgeniy S. Izmest’ev, Svetlana A. Rubtsova, Sergei V. Boichuk, Aigul R. Galembikova, Elena A. Smolyarchuk, Ilshat G. Mustafin, Airat R. Kayumov and Aleksandr V. Samorodov
Biomimetics 2023, 8(8), 570; https://doi.org/10.3390/biomimetics8080570 - 27 Nov 2023
Viewed by 1036
Abstract
Natural monoterpenes and their derivatives are widely considered the effective ingredients for the design and production of novel biologically active compounds. In this study, by using the molecular docking technique, we examined the effects of two series of “sulfide-sulfoxide-sulfone” thioterpenoids containing different (e.g., [...] Read more.
Natural monoterpenes and their derivatives are widely considered the effective ingredients for the design and production of novel biologically active compounds. In this study, by using the molecular docking technique, we examined the effects of two series of “sulfide-sulfoxide-sulfone” thioterpenoids containing different (e.g., bornane and pinane) monoterpene skeletons on the platelet’s aggregation. Our data revealed that all the synthesized compounds exhibit inhibitory activities on platelet aggregation. For example, compound 1 effectively inhibited platelet activation and demonstrated direct binding with CD61 integrin, a well-known platelet GPIIb-IIIa receptor on platelets. We further examined the antiaggregant activity of the most active compound, 1, in vivo and compared its activity with that of acetylsalicylic acid and an oral GPIIb-IIIa blocker, orbofiban. We found that compound 1 demonstrates antiaggregant activity in rats when administered per os and its activity was comparable with that of acetylsalicylic acid and orbofiban. Moreover, similarly, tirofiban, a well-known GPIIb-IIIa blocker, compound 1, effectively decreased the expression of P-selectin to the values similar to those of the intact platelets. Collectively, here, we show, for the first time, the potent antiaggregant activity of compound 1 both in vitro and in vivo due to its ability to bind with the GPIIb-IIIa receptor on platelets. Full article
(This article belongs to the Special Issue Blood-Compatible Materials: Preparation, Modification and Functionalization)
►▼ Show Figures

Figure 1

17 pages, 11019 KiB  
Article
Development of Composite Sponge Scaffolds Based on Carrageenan (CRG) and Cerium Oxide Nanoparticles (CeO2 NPs) for Hemostatic Applications
by Kimia Alizadeh, Yasaman Dezvare, Shirin Kamyab, Jhaleh Amirian, Agnese Brangule and Dace Bandere
Biomimetics 2023, 8(5), 409; https://doi.org/10.3390/biomimetics8050409 - 4 Sep 2023
Cited by 1 | Viewed by 1377
Abstract
In this study, a novel absorbable hemostatic agent was developed using carrageenan (CRG) as a natural polymer and cerium oxide nanoparticles (CeO2 NPs). CRG-CeO2-0.5 and CRG-CeO2-1 composites were prepared by compositing CeO2 to CRG + CeO2 [...] Read more.
In this study, a novel absorbable hemostatic agent was developed using carrageenan (CRG) as a natural polymer and cerium oxide nanoparticles (CeO2 NPs). CRG-CeO2-0.5 and CRG-CeO2-1 composites were prepared by compositing CeO2 to CRG + CeO2 at a weight ratio of 0.5:100 and 1:100, respectively. The physicochemical and structural properties of these compounds were studied and compared with pristine CRG. Upon incorporation of CeO2 nanoparticles into the CRG matrix, significant reductions in hydrogel degradation were observed. In addition, it was noted that CRG-CeO2 exhibited better antibacterial and hemostatic properties than CRG hydrogel without CeO2 NPs. The biocompatibility of the materials was tested using the NIH 3T3 cell line, and all samples were found to be nontoxic. Particularly, CRG-CeO2-1 demonstrated superior hemostatic effects, biocompatibility, and a lower degradation rate since more CeO2 NPs were present in the CRG matrix. Therefore, CRG-CeO2-1 has the potential to be used as a hemostatic agent and wound dressing. Full article
(This article belongs to the Special Issue Blood-Compatible Materials: Preparation, Modification and Functionalization)
►▼ Show Figures

Graphical abstract

15 pages, 6839 KiB  
Article
Bioactivity Features of a Zn-1%Mg-0.1%Dy Alloy Strengthened by Equal-Channel Angular Pressing
by Natalia Martynenko, Natalia Anisimova, Maria Shinkareva, Olga Rybalchenko, Georgy Rybalchenko, Mark Zheleznyi, Elena Lukyanova, Diana Temralieva, Artem Gorbenko, Arseny Raab, Natalia Pashintseva, Gulalek Babayeva, Mikhail Kiselevskiy and Sergey Dobatkin
Biomimetics 2023, 8(5), 408; https://doi.org/10.3390/biomimetics8050408 - 3 Sep 2023
Viewed by 923
Abstract
The structure, phase composition, corrosion and mechanical properties, as well as aspects of biocompatibility in vitro and in vivo, of a Zn-1%Mg-0.1%Dy alloy after equal-channel angular pressing (ECAP) were studied. The structure refinement after ECAP leads to the formation of elongated α-Zn grains [...] Read more.
The structure, phase composition, corrosion and mechanical properties, as well as aspects of biocompatibility in vitro and in vivo, of a Zn-1%Mg-0.1%Dy alloy after equal-channel angular pressing (ECAP) were studied. The structure refinement after ECAP leads to the formation of elongated α-Zn grains with a width of ~10 µm and of Mg- and Dy-containing phases. In addition, X-ray diffraction analysis demonstrated that ECAP resulted in the formation of the basal texture in the alloy. These changes in the microstructure and texture lead to an increase in ultimate tensile strength up to 262 ± 7 MPa and ductility up to 5.7 ± 0.2%. ECAP slows down the degradation process, apparently due to the formation of a more homogeneous microstructure. It was found that the alloy degradation rate in vivo after subcutaneous implantation in mice is significantly lower than in vitro ones. ECAP does not impair biocompatibility in vitro and in vivo of the Zn-1%Mg-0.1%Dy alloy. No signs of suppuration, allergic reactions, the formation of visible seals or skin ulcerations were observed after implantation of the alloy. This may indicate the absence of an acute reaction of the animal body to the Zn-1%Mg-0.1%Dy alloy in both states. Full article
(This article belongs to the Special Issue Blood-Compatible Materials: Preparation, Modification and Functionalization)
►▼ Show Figures

Figure 1

14 pages, 2695 KiB  
Article
New N-Methylimidazole-Functionalized Chitosan Derivatives: Hemocompatibility and Antibacterial Properties
by Natalia Drozd, Alexey Lunkov, Balzhima Shagdarova, Alla Il’ina and Valery Varlamov
Biomimetics 2023, 8(3), 302; https://doi.org/10.3390/biomimetics8030302 - 11 Jul 2023
Cited by 3 | Viewed by 1184
Abstract
Novel imidazole derivatives of the low molecular weight chitosan N-(2-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-3-ium chitosan chloride (NMIC) were synthesized using copper-catalyzed azide–alkyne cycloaddition (CuAAC). The degrees of substitution (DSs) for the new derivatives were 18–76%. All chitosan derivatives (2000 µg/mL) were completely soluble in water. The antimicrobial [...] Read more.
Novel imidazole derivatives of the low molecular weight chitosan N-(2-hydroxypropyl)-1H-1,2,3-triazol-4-yl)methyl)-1-methyl-1H-imidazol-3-ium chitosan chloride (NMIC) were synthesized using copper-catalyzed azide–alkyne cycloaddition (CuAAC). The degrees of substitution (DSs) for the new derivatives were 18–76%. All chitosan derivatives (2000 µg/mL) were completely soluble in water. The antimicrobial activity of the new compounds against E. coli and S. epidermidis was studied. The effect of chitosan derivatives on blood and its components was studied. NMIC samples (DS 34–76%) at a concentration <10 μg/mL had no effect on blood and plasma coagulation. Chitosan derivatives (DS 18–76%) at concentrations of ≥83 μg/mL in blood and ≥116.3 μg/mL in plasma resulted in a prolongation of the clotting time of blood and plasma, positively related to the DS. At concentrations up to 9.1 μg/mL, NMIC did not independently provoke platelet aggregation. The degree of erythrocyte hemolysis upon contact with NMIC samples (2.5–2500 μg/mL) was below 4%. The inhibition of blood/plasma coagulation indicates the promising use of the studied samples to modify the surface of medical materials in order to achieve thromboresistance. Full article
(This article belongs to the Special Issue Blood-Compatible Materials: Preparation, Modification and Functionalization)
►▼ Show Figures

Figure 1

Review

Jump to: Research

47 pages, 5956 KiB  
Review
Biomimetic Systems Involving Macrophages and Their Potential for Targeted Drug Delivery
by Ivan V. Savchenko, Igor D. Zlotnikov and Elena V. Kudryashova
Biomimetics 2023, 8(7), 543; https://doi.org/10.3390/biomimetics8070543 - 12 Nov 2023
Cited by 1 | Viewed by 1525
Abstract
The concept of targeted drug delivery can be described in terms of the drug systems’ ability to mimic the biological objects’ property to localize to target cells or tissues. For example, drug delivery systems based on red blood cells or mimicking some of [...] Read more.
The concept of targeted drug delivery can be described in terms of the drug systems’ ability to mimic the biological objects’ property to localize to target cells or tissues. For example, drug delivery systems based on red blood cells or mimicking some of their useful features, such as long circulation in stealth mode, have been known for decades. On the contrary, therapeutic strategies based on macrophages have gained very limited attention until recently. Here, we review two biomimetic strategies associated with macrophages that can be used to develop new therapeutic modalities: first, the mimicry of certain types of macrophages (i.e., the use of macrophages, including tumor-associated or macrophage-derived particles as a carrier for the targeted delivery of therapeutic agents); second, the mimicry of ligands, naturally absorbed by macrophages (i.e., the use of therapeutic agents specifically targeted at macrophages). We discuss the potential applications of biomimetic systems involving macrophages for new advancements in the treatment of infections, inflammatory diseases, and cancer. Full article
(This article belongs to the Special Issue Blood-Compatible Materials: Preparation, Modification and Functionalization)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop